| Samiratou Ouedraogo, Isidore Tiandiogo Traoré, Dramane Kania, Nongodo Firmin Kaboré, Ariane Mamguem Kamga, Hermann Badolo, Mimbouré Yara, Guillaume Sanou, Amariane Koné, Samdapawindé Thérèse Kagoné, Esperance Ouédraogo, Blahima Konaté, Rachel Médah, Nathalie Rekeneire, Armel Poda, Arnaud Eric Diendere, Boukary Ouédraogo, Oumar Billa, Gilles Paradis, Halidou Tinto, Tienhan Sandrine Dabakuyo-Yonli The burden of the coronavirus disease 2019 virus infection in Burkina Faso: Results from a World Health Organization UNITY population-based, age-stratified sero-epidemiological investigation Journal Article In: Influenza and other respiratory viruses, vol. 17, iss. 11, 2023, ISSN: 1750-2659. @article{Ouedraogo2023,
title = {The burden of the coronavirus disease 2019 virus infection in Burkina Faso: Results from a World Health Organization UNITY population-based, age-stratified sero-epidemiological investigation},
author = {Samiratou Ouedraogo and Isidore Tiandiogo Traor\'{e} and Dramane Kania and Nongodo Firmin Kabor\'{e} and Ariane Mamguem Kamga and Hermann Badolo and Mimbour\'{e} Yara and Guillaume Sanou and Amariane Kon\'{e} and Samdapawind\'{e} Th\'{e}r\`{e}se Kagon\'{e} and Esperance Ou\'{e}draogo and Blahima Konat\'{e} and Rachel M\'{e}dah and Nathalie Rekeneire and Armel Poda and Arnaud Eric Diendere and Boukary Ou\'{e}draogo and Oumar Billa and Gilles Paradis and Halidou Tinto and Tienhan Sandrine Dabakuyo-Yonli},
url = {https://pubmed.ncbi.nlm.nih.gov/38019697/},
doi = {10.1111/IRV.13216},
issn = {1750-2659},
year = {2023},
date = {2023-01-01},
journal = {Influenza and other respiratory viruses},
volume = {17},
issue = {11},
publisher = {Influenza Other Respir Viruses},
abstract = {Background: This study aimed to estimate the anti-SARS-CoV-2 antibody seroprevalence in the general population of Bobo-Dioulasso and Ouagadougou (Burkina Faso). Methods: We collected from March to April 2021 blood samples from randomly selected residents in both main cities based on the World Health Organization (WHO) sero-epidemiological investigations protocols and tested them with WANTAI SARS-CoV-2 total antibodies enzyme-linked immunosorbent assay (ELISA) kits intended for qualitative assessment. We also recorded participants' socio-demographic and clinical characteristics and information on exposure to SARS-CoV-2. Data were analysed with descriptive and comparative statistics. Results: We tested 5240 blood samples collected between 03 March and 16 April 2021. The overall test-adjusted seroprevalence for SARS-CoV-2 antibodies was (67.8% [95% CI 65.9\textendash70.2]) (N = 3553/3982). Seroprevalence was highest among participants aged 15\textendash18 years old (74.2% [95% CI 70.5\textendash77.5]) (N = 465/627), compared with those aged 10\textendash14 years old (62.6% [95% CI 58.7\textendash66.4]) (N = 395/631), or those over 18 (67.6% [95% CI 66.2\textendash69.1]) (N = 2693/3982). Approximately 71.0% (601/860) of participants aged 10\textendash18 years old who tested positive for SARS-CoV-2 antibodies experienced no clinical COVID-19 symptoms in the weeks before the survey, compared with 39.3% (1059/2693) among those aged over 18 years old. Conclusion: This study reports the results of the first known large serological survey in the general population of Burkina Faso. It shows high circulation of SARS-CoV-2 in the two cities and a high proportion of asymptomatic adolescents. Further studies are needed to identify the SARS-CoV-2 variants and to elucidate the factors protecting some infected individuals from developing clinical COVID-19.},
keywords = {Adolescent, Adult, Antibodies, Burkina Faso / epidemiology, Child, COVID-19* / epidemiology, doi:10.1111/irv.13216, Humans, Isidore Tiandiogo Traor\'{e}, MEDLINE, Middle Aged, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, PMC10655778, pmid:38019697, PubMed Abstract, Samiratou Ou\'{e}draogo, SARS-CoV-2*, Seroepidemiologic Studies, Surveys and Questionnaires, Tienhan Sandrine Dabakuyo-Yonli, Viral},
pubstate = {published},
tppubtype = {article}
}
Background: This study aimed to estimate the anti-SARS-CoV-2 antibody seroprevalence in the general population of Bobo-Dioulasso and Ouagadougou (Burkina Faso). Methods: We collected from March to April 2021 blood samples from randomly selected residents in both main cities based on the World Health Organization (WHO) sero-epidemiological investigations protocols and tested them with WANTAI SARS-CoV-2 total antibodies enzyme-linked immunosorbent assay (ELISA) kits intended for qualitative assessment. We also recorded participants' socio-demographic and clinical characteristics and information on exposure to SARS-CoV-2. Data were analysed with descriptive and comparative statistics. Results: We tested 5240 blood samples collected between 03 March and 16 April 2021. The overall test-adjusted seroprevalence for SARS-CoV-2 antibodies was (67.8% [95% CI 65.9–70.2]) (N = 3553/3982). Seroprevalence was highest among participants aged 15–18 years old (74.2% [95% CI 70.5–77.5]) (N = 465/627), compared with those aged 10–14 years old (62.6% [95% CI 58.7–66.4]) (N = 395/631), or those over 18 (67.6% [95% CI 66.2–69.1]) (N = 2693/3982). Approximately 71.0% (601/860) of participants aged 10–18 years old who tested positive for SARS-CoV-2 antibodies experienced no clinical COVID-19 symptoms in the weeks before the survey, compared with 39.3% (1059/2693) among those aged over 18 years old. Conclusion: This study reports the results of the first known large serological survey in the general population of Burkina Faso. It shows high circulation of SARS-CoV-2 in the two cities and a high proportion of asymptomatic adolescents. Further studies are needed to identify the SARS-CoV-2 variants and to elucidate the factors protecting some infected individuals from developing clinical COVID-19. |
